Skip to main content
Equibles
IMCR logo

IMCR · Immunocore Holdings plc

Track IMCR — free

Use IMCR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IMCR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$34.21 +0.01 (+0.03%) At close · Aug 14
Market Cap
$1.76B
Shares
51.50M

Immunocore Holdings plc Earnings Call Transcripts

Every quarterly earnings call for Immunocore Holdings plc (IMCR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $59.76M −$17.01M '23 Q2 23-06-30 · $70.16M −$19.73M '23 Q4 24-01-29 ▲26.2% $75.40M −$11.62M '24 Q2 24-08-08 ▲19.8% $84.05M −$23.77M '24 Q4 25-01-10 ▲29.9% $97.96M −$10.30M '25 Q2 25-08-07 ▲24.3% $104.48M −$30.06M '25 Q4 26-02-25 LATEST ▲18.3% $115.93M −$808,000 '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Q2 2026 Earnings Call
Revenue
$115.93M
▲ 18.3% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-13
25th Annual Needham Virtual Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-25
Immunocore Holdings plc Q4 FY2025 Earnings Call
Confident tone KIMTRAK commercial performance Cutaneous melanoma opportunity Pipeline expansion and Phase 3 trials
Revenue
$104.48M*
▲ 24.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q2
2025-08-07
Immunocore Holdings plc Q2 FY2025 Earnings Call
Confident tone TEBE-AM Phase III in second-line cutaneous melanoma KIMMTRAK commercial performance and global expansion Autoimmune pipeline expansion (T1D, second program)
Revenue
$97.96M
▲ 29.9% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Immunocore Holdings plc Q4 FY2024 Earnings Call
Confident tone KymTrah commercial performance and growth Infectious disease pipeline (HIV / HBV) Autoimmune programs
Revenue
$84.05M*
▲ 19.8% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-08-08
Immunocore Holdings plc Q2 FY2024 Earnings Call
Positive tone Pipeline and clinical readouts KIMMTRAK commercial performance European reimbursement challenges
Revenue
$75.40M
▲ 26.2% YoY
Diluted EPS
$-0.23
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-29
Immunocore Holdings plc Q4 FY2023 Earnings Call
Confident tone PRAME franchise (F106C, PRISM-MEL301) KIMMTRAK commercial performance TEBE-AM Phase 2/3 trial in cutaneous melanoma
Revenue
$70.16M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q2
2023-06-30
Immunocore Holdings plc Q2 FY2023 Earnings Call
Revenue
$59.76M
Diluted EPS
$-0.35
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Immunocore Holdings plc Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q2
2022-06-30
Immunocore Holdings plc Q2 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–10 of 10 earnings calls
Key facts CIK 1671927 CUSIP 45258D105 13F (30d) 135 filings 127 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)